Partnership PotentialImunon is optimistic about establishing a beneficial partnership due to the platform's preclinical proof of concept in infectious disease and oncology.
Regulatory AlignmentImunon has full FDA alignment for its OVATION 3 trial, which is a positive development for advancing their study.
Therapy EfficacyIMNN-001 therapy led to consistent and clinically meaningful improvements in key endpoints across treatment groups, including a 13-month increase in overall survival and a 3-month increase in progression-free survival compared to standard care.